login
register
Home
Getting Started
ChartMill Overview
Growth Traders
Technical Swing Traders
Long Term Investors
Tools
Stock Screener
Stock Charts
Full Screen Stock Charts
Market Monitor
Sectors
Earnings
Analyzer
Insider Trading
Up- and Downgrades
Stock Market
Top Gainers and Losers
New 52 Week High and Low
Gap Up and Gap Down
Most Active
Premarket Movers
After-Hours Movers
Earnings Calendar
USA Market Overview
Canada Market Overview
Europe Market Overview
Trading Ideas
News
Blog
Documentation
Documentation Center
Videos
Indicators
Properties
Screener Market data
Popular Articles
Bull Flags
Relative Strength
Pocket Pivots
Support and Resistance
RSI Indicator
MACD Indicator
Piotroski F-score
Squeeze Plays
Weinstein
Technical Breakout Setups
Trading Tips
Premarket Movers
Gap Up Stocks
Best Dividend Stocks
Bullish Engulfing Pattern
Ascending Triangle Pattern
Swing Trading
All articles ...
Subscriptions
Swing Trading Course
Account
Disclaimer
Affiliate
Contact
Privacy
ALNYLAM PHARMACEUTICALS INC (ALNY) Stock News
USA
- NASDAQ:ALNY -
US02043Q1076
-
Common Stock
491.22
USD
+9.55 (+1.98%)
Last: 10/20/2025, 5:32:20 PM
491.22
USD
0 (0%)
After Hours:
10/20/2025, 5:32:20 PM
Overview
Stock Chart
Technical Analysis
Fundamental Analysis
Analyst Ratings
Earnings Estimates
Financials
Ownership
News
ALNY Latest News, Press Relases and Analysis
All
Press Releases
14 days ago - By: Chartmill
ALNYLAM PHARMACEUTICALS INC (NASDAQ:ALNY) Shows Strong Technical Setup for Potential Breakout
6 hours ago - By: Zacks Investment Research
Why Alnylam (ALNY) Might be Well Poised for a Surge
4 days ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
6 days ago - By: Benzinga
$1000 Invested In Alnylam Pharmaceuticals 10 Years Ago Would Be Worth This Much Today
7 days ago - By: DataM Intelligence 4 Market Research LLP
Cardiovascular Drugs Market Size to Reach US$ 247.8 Billion by 2033, Driven by Rising Cardiovascular Disease Cases and Lifestyle Changes | According to DataM Intelligence
9 days ago - By: Benzinga
- Mentions:
EQIX
AEM
PLD
PSTG
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
18 days ago - By: Bloomberg
- Mentions:
BMY
ABBV
Alnylam Pulls TV Ad After Trump Crackdown on Drug Industry Spots
19 days ago - By: Zacks Investment Research
- Mentions:
NVS
PFE
BBIO
Can Alnylam's Broader Portfolio Ease Its Dependence on Amvuttra?
19 days ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
21 days ago - By: Alnylam Pharmaceuticals, Inc.
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
24 days ago - By: Investor's Business Daily
- Mentions:
XPH
PPH
XBI
IBB
...
Pharma Tariffs Back In Spotlight On New Trump Threat
a month ago - By: Illumina, Inc.
- Mentions:
ILMN
Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine
a month ago - By: Bloomberg
- Mentions:
PFE
BBIO
BridgeBio Says Pfizer, Alnylam Aren’t Playing Fair in Blockbuster Race
a month ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam Announces Pricing of Upsized Offering of $575 Million Convertible Senior Notes
a month ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam Announces Proposed Offering of $500 Million Convertible Senior Notes
a month ago - By: Zacks Investment Research
- Mentions:
PFE
BBIO
Can ALNY's Key Partnerships With Pharma Giants Drive Long-Term Growth?
2 months ago - By: Zacks Investment Research
Are Options Traders Betting on a Big Move in Alnylam Pharmaceuticals Stock?
2 months ago - By: Yahoo Finance
Should You Add Alnylam Pharmaceuticals (ALNY) to Your Portfolio?
2 months ago - By: Zacks Investment Research
- Mentions:
CRMD
KNSA
ALNY/RHHBY's Zilebesiran to Enter Phase III After Third Phase II Win
2 months ago - By: Alnylam Pharmaceuticals, Inc.
New Data From Landmark HELIOS-B Phase 3 Study Presented at ESC Congress 2025 Demonstrate Vutrisiran’s Long-Term Cardiovascular Benefit in ATTR-CM
2 months ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam to Advance Zilebesiran into Global Phase 3 Cardiovascular Outcomes Trial
2 months ago - By: Zacks Investment Research
- Mentions:
PFE
BBIO
Can Alnylam Rely on Amvuttra to Sustain Its Rapid Sales Momentum?
2 months ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam to Webcast Presentations at Upcoming September Investor Conferences
2 months ago - By: Yahoo Finance
- Mentions:
UNH
CNC
OSCR
ELV
...
Solar, biotech, and health insurance stocks are rising on Friday: here's why
2 months ago - By: Yahoo Finance
- Mentions:
TSLA
Profits May Be Just Around the Corner for This Strong-Buy Pharma Stock
2 months ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam to Present Progress in Transforming the Treatment of Cardiovascular Disease with RNAi Therapeutics at European Society of Cardiology Congress 2025
3 months ago - By: Alnylam Pharmaceuticals, Inc.
Alnylam to Webcast Presentation at Canaccord Genuity 45th Annual Growth Conference
3 months ago - By: Zacks Investment Research
Earnings Estimates Rising for Alnylam (ALNY): Will It Gain?
Please enable JavaScript to continue using this application.